CD22 | Other immune checkpoint proteins | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲


  Target has curated data in GtoImmuPdb

Target id: 2786

Nomenclature: CD22

Abbreviated Name: SIGLEC-2

Family: Other immune checkpoint proteins, Sialic acid binding Ig like lectins, CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 847 19q13.1 CD22 CD22 molecule
Previous and Unofficial Names
sialic acid binding Ig-like lectin 2 | SIGLEC-2 | B-lymphocyte cell adhesion molecule
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Parameter Reference
inotuzumab ozogamicin Hs Binding 9.7 pKd 2
pKd 9.7 (Kd 2x10-10 M) [2]
moxetumomab pasudotox Hs Binding 8.2 pKd 1,3-4
pKd 8.2 (Kd 6x10-9 M) [1,3-4]
Immunopharmacology Comments
CD22 (SIGLEC-2) is a B cell I-type (Ig-type) lectin that binds glycans containing sialic acids. It is involved in adhesion and activation. Mediates B cell-B cell interactions and may be involved in the localization of B cells in lymphoid tissues. Most SIGLECs inhibit immune cell activation, via immunoreceptor tyrosine-based inhibitory (ITIM) motifs in their cytosolic domains. Therefore, blockade of SIGLEC interactions restores immune cell activation, which is of interest for the treatment of B cell malignancies. CD22 is the target of the approved monoclonal antibody-drug conjugate (ADC) inotuzumab ozogamicin (FDA approved for ALL in 2017) and investigational ADC moxetumomab pasudotox.
Cell Type Associations
Immuno Cell Type:  B cells
Cell Ontology Term:   B cell (CL:0000236)


Show »

1. Beers R, Kreitman RJ, Pastan IH, Salvatore G. (2003) Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells. Patent number: WO2003027135. Assignee: Beers R, Kreitman RJ, Pastan IH, Salvatore G, US Gov Health & Human Serv. Priority date: 26/09/2001. Publication date: 03/04/2003.

2. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103 (5): 1807-14. [PMID:14615373]

3. Kreitman RJ, Pastan I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res., 17 (20): 6398-405. [PMID:22003067]

4. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol., 30 (15): 1822-8. [PMID:22355053]

How to cite this page

Other immune checkpoint proteins: CD22. Last modified on 01/11/2018. Accessed on 19/03/2019. IUPHAR/BPS Guide to PHARMACOLOGY,